← Back to Clinical Trials
RecruitingNCT02633553

Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionThymoma
SponsorFudan University
Study TypeINTERVENTIONAL
PhaseN/A
Enrollment238
SexALL
Min Age18 Years
Max Age75 Years
Start Date2018-01-10
Completion2025-12
Interventions
adjuvant radiotherapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This study is designed to investigate whether adjuvant radiotherapy after complete resection has a better survival for stage II or III thymoma.

Eligibility Criteria

Inclusion Criteria: 18\~75 years old; Eastern Cooperative Oncology Group performance status of 0 to 2; Pathologically confirmed masaoka stage II or III thymoma; Have adequate bone marrow, hepatic, and renal function; Patients receive complete resection within 3 months; Written informed consent. Exclusion Criteria: Patients with distant metastases; Patients underwent radiotherapy or chemotherapy; Patients who have malignancy history excluding carcinoma in situ of cervix in the previous five years; Active clinical pulmonary infection; Pregnant or nursing.

Related Trials

VIEW ON CLINICALTRIALS.GOV ↗ MORE THYMOMA TRIALS
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology